Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression.
Kian Huat LimZhou HanHyun Yong JeonJacob KachEnxuan JingSebastien Weyn-VanhentenryckMikaela DownsAnna CorrioneroRaymond S OhJuergen ScharnerAditya VenkateshSophina JiGene LiauBarry TichoHuw NashIsabel AznarezPublished in: Nature communications (2020)
While most monogenic diseases are caused by loss or reduction of protein function, the need for technologies that can selectively increase levels of protein in native tissues remains. Here we demonstrate that antisense-mediated modulation of pre-mRNA splicing can increase endogenous expression of full-length protein by preventing naturally occurring non-productive alternative splicing and promoting generation of productive mRNA. Bioinformatics analysis of RNA sequencing data identifies non-productive splicing events in 7,757 protein-coding human genes, of which 1,246 are disease-associated. Antisense oligonucleotides targeting multiple types of non-productive splicing events lead to increases in productive mRNA and protein in a dose-dependent manner in vitro. Moreover, intracerebroventricular injection of two antisense oligonucleotides in wild-type mice leads to a dose-dependent increase in productive mRNA and protein in the brain. The targeting of natural non-productive alternative splicing to upregulate expression from wild-type or hypomorphic alleles provides a unique approach to treating genetic diseases.
Keyphrases
- binding protein
- gene expression
- wild type
- protein protein
- amino acid
- genome wide
- dna methylation
- poor prognosis
- endothelial cells
- multiple sclerosis
- metabolic syndrome
- insulin resistance
- cancer therapy
- transcription factor
- type diabetes
- white matter
- copy number
- small molecule
- drug delivery
- adipose tissue
- resting state
- cerebral ischemia